Related Experiment Video

Updated: Oct 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate cancer in the late 1990s: hormone refractory disease options

J W Moul1, D R Lipo

  • 1Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Urologic Nursing
|January 14, 2000
PubMed

Insights

Advanced prostate cancer can cause painful bone metastases. New FDA-approved outpatient treatments, including chemotherapy and radioisotopes, offer effective palliation for bone pain and other symptoms in hormone-refractory prostate cancer patients.

Area of Science:

  • Oncology
  • Urology
  • Palliative Care

Background:

  • Prostate cancer is a leading cause of cancer death in American men.
  • Advanced prostate cancer frequently involves painful skeletal metastases.
  • Hormone-refractory prostate cancer presents challenges with bone pain and urinary obstruction.

Purpose of the Study:

  • To review current and emerging palliative treatments for painful bone metastases in advanced prostate cancer.
  • To inform urologic nursing personnel about new therapeutic options.

Main Methods:

  • Review of recent FDA-approved outpatient medications for palliation of bony metastases.
  • Discussion of chemotherapy (mitoxantrone with glucocorticoids) and radioisotope therapies (strontium-89, samarium-153-lexidronam).

Main Results:

  • Several new outpatient medications are effective for palliating painful bone metastases.
  • Mitoxantrone chemotherapy and specific radioisotopes provide complementary palliative options.

Conclusions:

  • Urologic nursing personnel require familiarity with novel palliative modalities for advanced prostate cancer.
  • These new treatments offer improved management for symptoms like bone pain and urinary obstruction.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...